Are you conducting an immuno-oncology clinical trial?
With the field of immuno-oncology constantly changing as a result of advances in cancer biology and immunology research,
an understanding of clinical biomarker testing is needed now more than ever. In this complimentary white paper
, learn about the importance of diverse clinical biomarker testing and the challenges diverse clinical biomarker requirements face in in these trials.
Also in this whitepaper, learn how Q2
Solutions is bringing 3 key research tools, including anatomic pathology
, flow cytometry
, and genomics
into immuno-oncology clinical trials in order to drive successful immuno-oncology studies for biopharma sponsors.
Meet the authors:
- Linda Robbie, Ph.D, Senior Director, Biomarkers and Global Translational Science Laboratory
- Radha Krishnan, M.D., Chief Pathologist and Senior Medical Director
- Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics
- Alistair J. Watt, Ph.D., Director, Translational Science Laboratory, Europe